Announcements Trials
Browse Landscape

Phase

Phase 2 2Phase 1 2Phase 1/2 1

Status

Active not recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Myeloid 4Other hematologic neoplasm 1

Conditions

Leukemia, Myeloid, Acute 481Leukemia 287Precursor Cell Lymphoblastic Leukemia-Lymphoma 249Leukemia, Lymphocytic, Chronic, B-Cell 235Myelodysplastic Syndromes 200Lymphoma 148Lymphoma, Non-Hodgkin 143Hematologic Neoplasms 139Recurrence 109Lymphoma, Mantle-Cell 102Lymphoma, Follicular 100Lymphoma, Large B-Cell, Diffuse 96Multiple Myeloma 82Leukemia, Myelogenous, Chronic, BCR-ABL Positive 81Leukemia, Myelomonocytic, Chronic 77Lymphoma, B-Cell, Marginal Zone 75Burkitt Lymphoma 72Hodgkin Disease 69Precursor T-Cell Lymphoblastic Leukemia-Lymphoma 52Lymphoma, B-Cell 50Neoplasms 47Waldenstrom Macroglobulinemia 46Myeloproliferative Disorders 44Blast Crisis 41Lymphoma, Large-Cell, Immunoblastic 38Leukemia, Myeloid, Chronic-Phase 35Leukemia, B-Cell 34Leukemia, Myeloid, Accelerated Phase 33Congenital Abnormalities 32Leukemia, Biphenotypic, Acute 31

Interventions

venetoclax 1pevonedistat 1Azacitidine 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 1/2 × Thrombocytosis × Other hematologic neoplasm × Clear all
NCT03862157 2026-03-11

Azacitidine, Venetoclax, and Pevonedistat in Treating Patients With Newly Diagnosed Acute Myeloid Leukemia

M.D. Anderson Cancer Center

Phase 1/2 Active not recruiting
40 enrolled
MyeloidOther hematologic neoplasm

Myelodysplastic Syndromes, Myeloproliferative Disorders, Polycythemia Vera, Thrombocythemia, Essential, Thrombocytosis, Leukemia, Neutrophilic, Chronic, Leukemia, Myeloid, Acute, Leukemia, Myelomonocytic, Chronic, Hypereosinophilic Syndrome, Leukemia, Myeloid, Chronic, Atypical, BCR-ABL Negative, Primary Myelofibrosis

Data powered by HemOnc (CC BY 4.0) Colophon âš¡